Upstream Bio, Inc.
UPBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. With a market capitalization of $329.2M, it sits in small-cap territory. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Market Cap
$329.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.17
EPS (TTM)
$-2.88
EPS (Fwd)
$-2.77
ROE
-46.1%
ROA
-30.3%
Cash
$261.3M
Total Debt
$954,000
Free CF
-$86.6M
52W Change
-67.0%
Annual Financials
Cash vs Debt
Where UPB stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, UPB finished 31.04% below its 150-day moving average ($9.60) and 53.58% below its 200-day moving average ($14.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UPB overbought or oversold?
At the September 1, 2026 close, UPB's RSI(14) was 43.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $261.3M in cash and $954K in debt, UPB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$86.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -46.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.2M (2022) to $2.9M (2025), reflecting a 135% increase over the period.
With cash comfortably exceeding debt, UPB has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Upstream Bio, Inc. and its sector.